Creating entirely new therapeutic vaccines for the treatment of cancer
DCPrime is dedicated to creating more effective immunotherapy products for the treatment of cancer. The company has developed a unique platform technology which allows the generation of off-the-shelf dendritic cell (DC)-based vaccines. The platform combines the power of DC-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. With this powerful platform, DCPrime has the opportunity to become the gold standard for off-the-shelf dendritic cell product.
February 1, 2012
European Medicines Agency approves Orphan Medicinal Product application of DCPrime's Acute Myeloid Leukemia vaccine
January 1, 2012
DCPrime BV expands management team
November 11, 2011
DCPrime BV: Kansen realiseren dankzij financiële steun
December 12, 2011
"Could this be the end of cancer? " by Sharon Begley, The Daily Beast Magazine
Latest DCPrime News:
February 1, 2012
European Medicines Agency approves Orphan Medicinal Product application of DCPrime's Acute Myeloid Leukemia vaccine
January 1, 2012
DCPrime BV expands management team
November 11, 2011
DCPrime BV: Kansen realiseren dankzij financiële steun
Other News:
December 12, 2011
"Could this be the end of cancer? " by Sharon Begley, The Daily Beast Magazine
